Pieris Pharmaceuticals has entered into a research collaboration and license agreement with Genentech to discover, develop and commercialise locally delivered respiratory and ophthalmology therapies that leverage its proprietary Anticalin tech platform.
The research collaboration will enable Pieris to combine its robust discovery engine with Genentech’s targets, as well as its preclinical and clinical development expertise, to create novel therapies for the treatment of respiratory and ophthalmological diseases.
These two focus areas of the collaboration are uniquely suited to the advantages offered by the small size of Anticalin proteins when delivered locally.
“We look forward to working closely with Genentech on the development of new inhaled and ophthalmological treatments based on the Anticalin platform,” said Stephen S. Yoder, President and CEO of Pieris.
“This collaboration further expands our partnered efforts in respiratory diseases and opens a new avenue for our Anticalin technology to potentially provide patient benefit through local biological effects.
“This is our second respiratory alliance with a major biopharma company, and we remain deeply committed to inhaled biologics, which have already shown benefit in the clinic. We also look forward to pursuing another local application of our technology in ophthalmology, where Genentech has extensive capabilities.”
Pieris will receive $20 million as an upfront payment and may be eligible to receive more than $1.4 billion in additional milestone payments across multiple programs, as well as tiered royalties for commercialised programs.
Pieris will be responsible for discovery research and early preclinical development of the programs, and Genentech will be responsible for IND-enabling activities, clinical development, and commercialisation of those programs.
Genentech, a Roche member, will also have the option to select additional targets in return for an option exercise fee.
The collaboration does not include any of Pieris’ internal programs.